A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: This retrospective observational study explored the therapeutic potential of combined androgen blockade (CAB) with bicalutamide (Bic-CAB) as an initial treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in Japan. METHODS: The electronic health records of 159 patients with mHSPC from three Japanese institutions who received initial treatment with Bic-CAB between 2007 and 2017 were analyzed. The time to prostate-specific antigen (PSA) progression, duration of Bic-CAB treatment, and overall survival (OS), with various definitions for PSA progression, were assessed. A multivariate Cox proportional hazards model was constructed using clinical parameters to predict time to the end of Bic-CAB treatment and OS. RESULTS: The median observation period was 46.4 months, and the median age of patients at diagnosis was 71 years. A total of 46.5% patients experienced PSA progression with a median survival duration of 29 months (according to Prostate Cancer Clinical Trials Working Group 3 criteria), and 49.1% patients achieved a PSA nadir < 0.2 ng/mL in a median time of 4.7 months. When stratified by PSA nadir and PSA change, patients at low risk for disease progression with a small PSA change due to low initial PSA had a 5-year OS of 100% and a 10-year OS of 75%. The OS during the observation period was 72.9 months. CONCLUSION: These findings highlight the potential effect of Bic-CAB in patients with mHSPC who were at low risk for disease progression. Initial treatment with Bic-CAB and adjusting treatment early based on PSA dynamics may be a reasonable treatment plan for these patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide
- Date Crossref
- 17/08/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kyoto University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Otsu Red Cross Hospital pays non établi dans la noticeÉtablissement de santé
-
Nagoya University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
University of Miyazaki Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
University of Fukui Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Kumamoto University pays non établi dans la noticeUniversité ou école supérieure
-
Astellas Pharma (Japan) pays non établi dans la noticeEntreprise
-
Japanese Red Cross Otsu Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Graduate School of Medical Sciences Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Astellas Pharma Inc pays non établi dans la noticeEntreprise
Department of Urology — Kyoto University, Otsu Red Cross Hospital et Department of Urology — Nagoya University, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.